Crossmark

Primary prophylaxis with mTOR inhibitor enhances T cell effector function and prevents heart transplant rejection during talimogene laherparepvec therapy of squamous cell carcinoma

Crossref DOI link: https://doi.org/10.1038/s41467-024-47965-3

Published Online: 2024-04-30

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Joo, Victor

Abdelhamid, Karim https://orcid.org/0000-0002-0627-4585
Noto, Alessandra

Latifyan, Sofiya

Martina, Federica

Daoudlarian, Douglas https://orcid.org/0000-0002-5854-9253
De Micheli, Rita

Pruijm, Menno

Peters, Solange https://orcid.org/0000-0002-0412-7143
Hullin, Roger

Gaide, Olivier https://orcid.org/0000-0002-2865-7595
Pantaleo, Giuseppe https://orcid.org/0000-0003-3651-2721
Obeid, Michel https://orcid.org/0000-0003-2095-2677
License Information

Text and Data Mining valid from 2024-04-30

Version of Record valid from 2024-04-30
More Information

Article History

Received: 3 August 2023

Accepted: 15 April 2024

First Online: 30 April 2024

Competing interests

: All authors declare no competing interests.

Document is current

Any future updates will be listed below